RT Journal Article SR Electronic T1 Long-term retention on antiretroviral therapy among infants, children, adolescents and adults in Malawi: A cohort study JF medRxiv FD Cold Spring Harbor Laboratory Press SP 19010322 DO 10.1101/19010322 A1 Catrina Mugglin A1 Andreas Haas A1 Joep van Oosterhout A1 Malango Msukwa A1 Lyson Tenthani A1 Janne Estill A1 Matthias Egger A1 Olivia Keiser YR 2019 UL http://medrxiv.org/content/early/2019/11/02/19010322.abstract AB Objectives: We examine long-term retention of adults, adolescents and children on antiretroviral therapy under different HIV treatment guidelines in Malawi. Design: Prospective cohort study. Setting and participants: Adults and children starting ART between 2005 and 2015 in 21 health facilities in southern Malawi. Methods: We used survival analysis to assess retention at clinic level, Cox regression to examine risk factors for loss to follow up, and competing risk analysis to assess long-term outcomes of people on antiretroviral therapy (ART). Results: We included 132,274 individuals in our analysis, totalling 270,256 person years of follow up (PYFU; median per patient 1.3, interquartile range (IQR) 0.26-3.1), 62% were female and the median age was 32 years. Retention on ART was lower in the first year on ART compared to subsequent years for all guideline periods and age groups. Infants (0-3 years), adolescents and young adults (15-24 years) were at highest risk of LTFU. Comparing the different calendar periods of ART initiation we found that retention improved initially, but remained stable thereafter. Conclusion: Even though the number of patients and the burden on health care system increased substantially during the study period of rapid ART expansion, retention on ART improved in the early years of ART provision, but gains in retention were not maintained over 5 years on ART. Reducing high attrition in the first year of ART should remain a priority for ART programs, and so should addressing poor retention among adolescents, young adults and men.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Bill and Melinda Gates Foundation (OPP1090200), and the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under Award Number U01AI069924. CM was supported by a MD-PhD fellowship from Schweizerische Akademie der Medizinischen Wissenschaften (SAMW). OK was supported by a professorship grant from the Swiss National Science Foundation (SNF) (163878) and AH was partly supported by a SNF Early Postdoc.Mobility Fellowship (P2BEP3_178602). These funding organizations did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of author’s salaries and research material.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are available from the corresponding author on request, conditional on approval by the Malawi Ministry of Health.